News Sort by Year All Years 2022 (29) 2021 (17) 2020 (19) 2019 (12) 2018 (18) 2017 (19) 2016 (32) 2015 (43) 2014 (50) 2013 (32) 2012 (17) Search December 1, 2022 Theriva Biologics to Participate in Upcoming Investor Conferences November 10, 2022 Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results November 10, 2022 Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results November 3, 2022 Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients November 3, 2022 Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results October 31, 2022 Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics October 24, 2022 Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck October 12, 2022 Synthetic Biologics Rebrands as Theriva Biologics September 30, 2022 Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma September 27, 2022 Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
